Business
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&ASARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on Tuesday, May 20, 2025 at 4:00 PM ET to discuss the growing unmet medical need in concussion treatment and provide an overview of
About this update from Oragenics Inc.
[{"type":"image","alt":"Oragenics","displaySize":"","headline":null,"caption":"Oragenics","className":"","disableSlideshowImg":false,"size":{"original":{"width":256,"height":256,"url":"https://media.zenfs.com/en/globenewswire.com/0212681d7f415be924a60d8016c09110"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ol2bqPWKKXmUHXexVg71mg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/0212681d7f415be924a60d8016c09110","width":256,"height":256}},"lazy":false},{"type":"text","content":"Webinar to Feature CEO Janet Huffman, Chief Clinical Officer Dr. Frank Peacock, and Dr. James Kelly, Followed by Live Q&A","length":125,"tagName":"p"},{"type":"text","content":"SARASOTA, Fla., May 12, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced it will host a management update webinar on Tuesday, May 20, 2025 at 4:00 PM ET to discuss the growing unmet medical need in concussion treatment and provide an overview of its lead program, ONP-002, a proprietary neuroprotective therapy designed for the treatment of mild traumatic brain injury (mTBI), also known as concussion.","length":535,"tagName":"p"},{"type":"text","content":"The live webinar will feature presentations from:","length":49,"tagName":"p"},{"type":"text","content":"● Janet Huffman, Chief Executive Officer of Oragenics ● Dr. James Kelly, Chief Medical Officer of Oragenics ● Frank Peacock, MD, Chief Clinical Officer of Oragenics and a nationally recognized expert in emergency medicine","length":223,"tagName":"p"},{"type":"text","content":"Webinar Details ","length":15,"tagName":"p"},{"type":"text","content":"● Title: Addressing the Unmet Needs in Concussion Treatment: The Promise of ONP-002 ● Date: Tuesday, May 20, 2025 ● Time: 4:00 PM ET","length":134,"tagName":"p"},{"type":"text","content":"The live webcast and replay will be available in the Investor Relations section of the Oragenics website at https://ir.oragenics.com/.","length":134,"tagName":"p"},{"type":"text","content":"“Concussions continue to be one of the most pervasive and underserved injuries in both sports and civilian trauma,” said Janet Huffman, CEO of Oragenics. “ONP-002 offers a novel therapeutic approach to a market with no FDA-approved drug therapies, and this w...